How to reduce a risk of venous thromboembolism while taking combined oral contraceptives

Q3 Medicine

Obstetrics, Gynecology and Reproduction Pub Date : 2023-07-16 DOI:10.17749/2313-7347/ob.gyn.rep.2023.422

V. Bitsadze, J. Khizroeva, A. Solopova, M. V. Kvaratskheliia, D. Y. Zabolotnaya, Z. Xiaoxia, M. Tretyakova, V. Tsibizova, N. R. Gashimova, K. Grigoreva, M. A. Gileva, A. Shkoda, J. Gris, A. Makatsariya

{"title":"How to reduce a risk of venous thromboembolism while taking combined oral contraceptives","authors":"V. Bitsadze, J. Khizroeva, A. Solopova, M. V. Kvaratskheliia, D. Y. Zabolotnaya, Z. Xiaoxia, M. Tretyakova, V. Tsibizova, N. R. Gashimova, K. Grigoreva, M. A. Gileva, A. Shkoda, J. Gris, A. Makatsariya","doi":"10.17749/2313-7347/ob.gyn.rep.2023.422","DOIUrl":null,"url":null,"abstract":"The review presents data on the evolution of combined oral contraceptives (COCs), related most frequent and dangerous side effects including venous thromboembolism (VTE). The issue of VTE upon administration of COCs is highlighted, and the risks of such complication in patients receiving hormonal contraception are determined. The issues of the basic demands of women choosing COCs are considered as well as current opportunities to meet such requests by using novel drug groups with a high profile of efficacy and safety. Particular cases of optimal COCs choice for patients with specific comorbidities such as obesity, hirsutism, seborrhea, alopecia, acne, polycystic ovary syndrome (PCOS), fibrocystic mastopathy, endometriosis as well as in case of gynecological surgical interventions are analyzed. The options of contraceptive therapy are proposed by taking into account individual female wishes (lack of weight gain, decreased libido, etc.).","PeriodicalId":36521,"journal":{"name":"Obstetrics, Gynecology and Reproduction","volume":"132 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrics, Gynecology and Reproduction","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.422","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The review presents data on the evolution of combined oral contraceptives (COCs), related most frequent and dangerous side effects including venous thromboembolism (VTE). The issue of VTE upon administration of COCs is highlighted, and the risks of such complication in patients receiving hormonal contraception are determined. The issues of the basic demands of women choosing COCs are considered as well as current opportunities to meet such requests by using novel drug groups with a high profile of efficacy and safety. Particular cases of optimal COCs choice for patients with specific comorbidities such as obesity, hirsutism, seborrhea, alopecia, acne, polycystic ovary syndrome (PCOS), fibrocystic mastopathy, endometriosis as well as in case of gynecological surgical interventions are analyzed. The options of contraceptive therapy are proposed by taking into account individual female wishes (lack of weight gain, decreased libido, etc.).

查看原文本刊更多论文

如何在服用联合口服避孕药时降低静脉血栓栓塞的风险

这篇综述介绍了复方口服避孕药(COCs)的演变，以及相关的最常见和最危险的副作用，包括静脉血栓栓塞(VTE)。本研究强调了服用COCs后静脉血栓栓塞的问题，并确定了接受激素避孕的患者发生此类并发症的风险。考虑了妇女选择COCs的基本需求问题，以及目前通过使用具有高度有效性和安全性的新型药物组来满足这些要求的机会。针对肥胖、多毛症、脂溢症、脱发、痤疮、多囊卵巢综合征(PCOS)、纤维囊性乳房病、子宫内膜异位症等特殊合并症患者以及妇科手术干预患者，分析了最佳COCs选择的具体案例。避孕疗法的选择是根据女性的个人意愿提出的(不增加体重，性欲下降等)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊